Colorectal cancer is the third most common cancer and is a leading cause of cancer death in the United States.1BRAF (OMIM 164757) V600E–mutated colorectal cancer represents a discrete subtype that is found in approximately 10% of patients with metastatic disease.2 Previous work has demonstrated that patients with BRAF V600E sequence variation have inferior clinical outcomes compared with patients with BRAF wild-type,3,4,5 with a median overall survival of 4 to 6 months after failure of initial therapy.2 Here, BRAF is linked to cancer.